Plain English summary not yet available
The full original text is available below. Check back soon as we process this bill.
I
116TH CONGRESS
1ST SESSION H. R. 5381
To amend the Federal Food, Drug, and Cosmetic Act to require the label
of a drug to list the country of origin of each of the drug’s active ingredients.
IN THE HOUSE OF REPRESENTATIVES
DECEMBER 10, 2019
Mr. DESJARLAIS introduced the following bill; which was referred to the
Committee on Energy and Commerce
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to
require the label of a drug to list the country of origin
of each of the drug’s active ingredients.
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled,
2
SECTION 1. SHORT TITLE.
3
This Act may be cited as the ‘‘International Pharma-
4
ceutical Transparency Act of 2019’’.
5
SEC. 2. COUNTRY-OF-ORIGIN LABELING FOR ACTIVE IN-
6
GREDIENTS IN DRUGS.
7
(a) MISBRANDING.—Section 502 of the Federal
8
Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amend-
9
ed by adding at the end the following:
10
VerDate Sep 11 2014
00:25 Dec 14, 2019
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H5381.IH
H5381
pamtmann on DSKBC07HB2PROD with BILLS
2
•HR 5381 IH
‘‘(ee) If it is a drug and its label fails to list the coun-
1
try of origin of each of its active ingredients.’’.
2
(b) APPLICABILITY.—Section 502(ee) of the Federal
3
Food, Drug, and Cosmetic Act, as added by subsection
4
(a), applies beginning on the day that is 6 months after
5
the date of enactment of this Act.
6
Æ
VerDate Sep 11 2014
00:25 Dec 14, 2019
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6301
E:\BILLS\H5381.IH
H5381
pamtmann on DSKBC07HB2PROD with BILLS